Staff Profile
Dr Tom Andrew
Academic Plastic and Reconstructive Surgeon
- Email: tom.andrew@ncl.ac.uk
- Telephone: +44 (0) 191 208 7170
- Address: Translation and Clinical Research Institute
Newcastle University Centre for Cancer
The Medical School,
Framlington Place,
Newcastle upon Tyne,
NE2 4HH
Mr. Tom William Andrew is an Academic Plastic Surgery Registrar at Newcastle University and a Hunterian Professor of the Royal College of Surgeons of England. His research lies at the intersection of artificial intelligence (AI), digital healthcare, and precision oncology, with a focus on aggressive skin cancers and head and neck malignancies.
Currently completing his PhD at Newcastle University, Tom is at the forefront of multimodal AI research, integrating deep learning, feature engineering, and clinical trial methodologies to enhance prognostication and treatment stratification in surgical oncology. He develops advanced AI driven decision support systems for personalised surgical care, translating insights into real-world clinical applications to shape the future of digital health and AI enhanced surgery.
Tom’s academic career includes a Research Scholarship at Stanford University, where he contributed to computational biology and regenerative medicine research, and advanced study in Neural Networks and Deep Learning at Johns Hopkins University. His work has received significant international recognition, including funding from Cancer Research UK, and has led to high-impact publications and global collaborations in AI-driven oncology.
As a rising leader in digital clinical research, Tom is dedicated to transforming cancer care through clinical translation, AI enabled diagnostics, and novel digital healthcare solutions.
Tom’s research focuses on multimodal AI, digital biomarkers, and clinical translation in surgical oncology, with particular emphasis on:
• Deep learning and predictive modeling for personalised cancer care
• AI-driven risk stratification for aggressive skin and head & neck cancers
• Feature engineering and explainable AI for clinical decision support
• Digital healthcare solutions to bridge AI research and real-world clinical practice
• Clinical trial methodologies to validate AI in oncological decision-making
His work has led to the development of AI powered clinical decision tools, with applications in real time prognostication, treatment response prediction, and surgical planning. He has presented his research at major international conferences (NIH, ASCO, AAD) and collaborates with leading institutions on next generation AI applications in surgical oncology.
-
Articles
- Andrew TW, Erdmann S, Alrawi M, Plummer R, Shalhout SZ, Sondak V, Brownell I, Lovat PE, Rose A. A multivariable disease-specific model enhances prognostication beyond current Merkel cell carcinoma staging: An international cohort study of 10,958 patients. Journal of the American Academy of Dermatology 2025, 92(3), 520-527.
- Andrew TW, Alrawi M, Plummer R, Reynolds N, Sondak V, Brownell I, Lovat PE, Rose A, Shalout SZ. A hybrid machine learning approach for the personalized prognostication of aggressive skin cancers. npj Digital Medicine 2025, 8, 15.
- Ewen T, Husain A, Stefanos N, Barrett P, Jones C, Ness T, Long A, Horswell S, Bosomworth H, Lowenstein J, Richardson G, Swan D, McConnell A, Rose A, Andrew T, Reynolds N, Malvehy J, Carrera C, Alos L, Mailer S, Helm T, Ding L, Bogner P, Podlipnik S, Puig S, McArthur GA, Paragh G, Labus M, Sloan P, Armstrong JL, Lovat PE. Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma. British Journal of Dermatology 2024, 190(4), 549-558.